When was AMW founded?

AMW was founded in 2008 and raised its 1st funding round 6 years after it was founded.

Where is AMW located?

AMW is headquartered in Warngau, Germany.

How many employees does AMW have?

As of Sep 30, 2026, the latest employee count at AMW is 98.

Is AMW a funded company?

AMW is a funded company, having raised a total of $6.36M across 4 funding rounds to date. The company's 1st funding round was a $***** Series B round, raised on Aug 26, 2014.

When was the latest funding round of AMW?

AMW's latest funding was a $***** Conventional Debt round on Jan 04, 2018, with participation from 1 investor.

Where does AMW rank among its competitors?

AMW ranks 162nd amongst 1972 active competitors, of which 449 are funded. It stands 10th in terms of total funding among its competitors. The most recent competitor to raise funding was LifeMine Therapeutics, which secured $75M in Aug, 2026.

Who are the top competitors of AMW?

AMW's top competitors include Antheia, Transcenta and Akeso. Among them, LifeMine Therapeutics secured the most recent funding round in August, 2026.

AMW - 2026 Company Profile, Team, Funding & Competitors

AMW is an acquired company based in Warngau (Germany), founded in 2008 by Wilfried Fischer. It operates as a Transdermal drug delivery technologies. AMW has raised $6.36M in funding. The company has 1972 active competitors, including 449 funded and 319 that have exited. Its top competitors include companies like Antheia, Transcenta and Akeso.

Company Details

AMW develops and manufactures transdermal drug delivery technologies. Their products are active-ingredient patches and implants. They develop therapeutic solutions for oncology, neurology, dermatology and pain treatment.

Website: a-m-w.eu
Email ID: *****@a-m-w.eu
Phone Number: +49 **********

Key Metrics

Founded Year

2008

Location

Warngau, Germany

Stage

Acquired

Total Funding

$6.36M in 4 rounds

Latest Funding Round

Conventional Debt, Jan 04, 2018, $*****

Investors

IPF Partners & 8 more

Ranked

162^nd among 1972 active competitors

Employee Count

98 as on Sep 30, 2026

Similar Companies

Antheia & 2678 more

Exit Details

Acquired by Yunfeng Capital (Jul 05, 2018)

View AMW's full profile

AMW is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Reports
Amw Gmbh CIN: HRB174568 , Germany, Active	Dec 31, 2007	-	78 (As on Dec 31, 2021)

AMW got acquired by Yunfeng Capital and Hybio Pharmaceutical on Jul 05, 2018.

Click here to take a look at AMW's acquisition in detail

AMW has raised a total funding of $6.36M over 4 rounds. Its first funding round was on Aug 26, 2014. Its latest funding round was a Conventional Debt round on Jan 04, 2018 for $*****. 1 investor participated in its latest round. AMW has 9 institutional investors.

Here is the list of recent funding rounds of AMW:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jan 04, 2018	2844817	Conventional Debt	6373850	9062070	2621337	1059819
Nov 2017	3987567	Conventional Debt	1233951	8615180	8755355	8770400
Jul 21, 2016	1604956	Series C	6905284	7879593	5413979	Bayern Kapital & 5 more

Access funding benchmarks and valuations. Sign up today!

View details of AMW's funding rounds and investors

The founders of AMW is Wilfried Fischer. Philipp Karbach and Friedrich Tegel are the CEOs of AMW.

Here are the details of AMW's key team members:

Wilfried Fischer: Founder of AMW.
Friedrich Tegel: CEO of AMW.

View details of AMW's Founder profiles and Board Members

AMW's employee count trend

AMW has 98 employees as of Sep 26. Here is AMW's employee count trend over the years:

Uncover AMW's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of AMW include Antheia, Transcenta and Akeso. Here is the list of Top 10 competitors of AMW, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Antheia 2013, Palo Alto (United States), Series C	Genetically engineered yeast cells to produce medicinal products	$176M	Viking Global Investors, ATHOS KG & 15 others	67/100
2nd	Transcenta 2019, Suzhou (China), Public	Developer of antibody-based therapeutics	$205M	Lilly Asia Ventures, Temasek & 11 others	66/100
3rd	Akeso 2012, Zhongshan (China), Public	Developer of antibody drug conjugates for the treatment of broad spectrum diseases	$195M	Loayal Valley Capital, Sino Biopharmaceutical ... & 18 others	65/100
4th	Korro Bio 2018, Cambridge (United States), Public	Provider of RNA editing technologies to develop genetic medicines for rare and prevalent diseases	$4M	Cormorant Asset Management, Atlas Venture ... & 14 others	64/100
5th	Novogene Corporation 2011, Beijing (China), Series B	Provider of genomic services and solutions	$75M	SDIC Innovation, CMB International Capital ... & 4 others	64/100
6th	Fermentalg 2005, Libourne (France), Public	Innovating with algae for sustainable solutions in nutrition and environmental impact	$30.3M	Demeter, Smalt Capital & 14 others	63/100
7th	Microban 1994, Huntersville (United States), Acquired	Antimicrobial and odor control technologies for durable product protection and freshness	$64.6M	TA Associates, UBS & 1 others	63/100
8th	LifeMine Therapeutics 2016, Watertown (United States), Series E	Developer of novel drugs from fungi via genome mining and recombinant overexpression	$563M	Fidelity Investments, 6 Dimensions Capital ... & 17 others	62/100
9th	Dewpoint Therapeutics 2018, Boston (United States), Series D	Developer of small molecule based therapeutics	$364M	Maverick Ventures, SoftBank Vision Fund & 16 others	62/100
10th	One Biosciences 2020, Paris (France), Series A	Developer of single-cell therapeutics solutions to treat multiple health disorders	$22.4M	BLAST Premier, Redmile Group & 6 others	62/100
162nd	AMW 2008, Warngau (Germany), Acquired	Transdermal drug delivery technologies	$6.36M	IPF Partners, European Investment Bank & 7 others	45/100